exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088167 RNA Name: hsa-miR-330-3p RNA Type: miRNA Chromosome: chr19 Starnd: - Coordinate: Start Site(bp): 45639009 End Site(bp): 45639031 External Links: hsa-miR-330-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ANP32B chr9 97983341 98015943 + ATRX chrX 77504878 77786233 - BCL2L11 chr2 111119378 111168445 + CBX2 chr17 79778148 79787983 + CCSER2 chr10 84328586 84518521 + CRCP chr7 66114604 66154568 + DAG1 chr3 49468703 49535618 + ERLIN1 chr10 100150094 100186033 - GNAI2 chr3 50226292 50259362 + HNRNPAB chr5 178204533 178211163 + MRFAP1 chr4 6640091 6642745 + MTMR12 chr5 32226994 32312987 - NPAT chr11 108157215 108222638 - PFN1 chr17 4945652 4949061 - PKN2 chr1 88684222 88836255 + RAB10 chr2 26034084 26137454 + SNX27 chr1 151612006 151699091 + TNKS chr8 9555912 9782346 + TOMM34 chr20 44942130 44960397 - TRIM25 chr17 56836387 56914080 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000591 chr15 41961025 41962156 + hsa_circ_0000540 chr14 55799534 55821940 + hsa_circ_0001731 chr7 100731990 100738448 + hsa_circ_0001168 chr20 47691321 47707559 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC020978.7 chr16 68224713 68227734 + AC079781.5 chr7 97851688 97972985 - AC124045.1 chr3 44667412 44669364 + AC125257.1 chr17 41848518 41851447 - AL132655.1 chr20 58833809 58836529 - AL137129.1 chr14 61734138 61776260 + AL157392.3 chr10 13631143 13668445 + FGD5-AS1 chr3 14920347 14948424 - MIR663AHG chr20 26167817 26251546 - NEAT1 chr11 65422774 65445540 + OIP5-AS1 chr15 41283990 41309737 + SNHG25 chr17 64145970 64146476 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.